FCGRT and myasthenia gravis: In a systematic review published in early 2024 assessing the safety and efficacy of FcRn inhibitors in patients with myasthenia gravis with the exception of rozanolixizumab all FcRn inhibitors demonstrated safety profiles comparable to placebo [106].